Press releases

Orchard Therapeutics Announces $110M Series B Financing to Advance Transformative Gene Therapy Pipeline

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing

Read more

Orchard Therapeutics and Généthon Announce Gene Therapy alliance in X-linked Chronic Granulomatous Disease

Orchard Therapeutics announces today a strategic alliance with Généthon, to develop gene therapy for X-linked chronic granulomatous disease (“X-CGD”)

Read more

Orchard Therapeutics Announces Expansion of Technical Operations in California

Orchard Therapeutics, today announced the opening of a second facility for technical operations in the San Francisco Bay Area

Read more

Orchard Therapeutics announces extension of its collaboration with Manchester University to include Sanfilippo Syndrome type B

Orchard Therapeutics Limited, announces today that it has acquired an exclusive license to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester, UK

Read more

Bringing next-generation gene therapy to the clinic

An interview of Dr. Andrea Spezzi by UCL Innovation Forum

Read more